A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs GOVX-B21 (Primary) ; MVA-HIV62 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 20 Oct 2016 According to a GeoVax media release, clinical data from this study was presented at the HIV Research for Prevention, Partnering for Prevention (HIVR4P) conference.